FDA Lifts Clinical Holds On Anemia Compounds Under Development By Astellas/FibroGen
FDA approves protocols proposed by FibroGen to resume Phase II trials of FG-2216 and FG-4592.
FDA approves protocols proposed by FibroGen to resume Phase II trials of FG-2216 and FG-4592.